# OnCo record nct04787042 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04787042/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04787042", "NCT04787042" ;
  schema:name "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067"@en ;
  schema:description "A phase 1/2 trial of Obinutuzumab, Pembrolizumab in melanoma and renal cell carcinoma, run by Simcha IL-18, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04787042/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04787042> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-08-06" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/pembrolizumab/> .